Oxford BioMedica (LON:OXB) Price Target Increased to GBX 16 by Analysts at Peel Hunt

Oxford BioMedica (LON:OXB) had its price objective lifted by Peel Hunt from GBX 13 ($0.18) to GBX 16 ($0.22) in a research report sent to investors on Thursday, March 15th. Peel Hunt currently has a buy rating on the biopharmaceutical company’s stock.

Shares of LON OXB traded up GBX 0.36 ($0.01) during trading on Thursday, hitting GBX 10.96 ($0.15). The company had a trading volume of 7,792,549 shares, compared to its average volume of 6,890,000. Oxford BioMedica has a fifty-two week low of GBX 4.44 ($0.06) and a fifty-two week high of GBX 13.19 ($0.19).

How to Become a New Pot Stock Millionaire

In related news, insider Peter Nolan purchased 371,450 shares of Oxford BioMedica stock in a transaction dated Thursday, April 5th. The shares were acquired at an average cost of GBX 11 ($0.15) per share, with a total value of £40,859.50 ($57,354.72). Also, insider Lorenzo Tallarigo purchased 22,066 shares of Oxford BioMedica stock in a transaction dated Thursday, March 22nd. The stock was bought at an average cost of GBX 12 ($0.17) per share, for a total transaction of £2,647.92 ($3,716.90). Insiders have purchased 415,637 shares of company stock worth $4,616,194 over the last 90 days.

COPYRIGHT VIOLATION WARNING: “Oxford BioMedica (LON:OXB) Price Target Increased to GBX 16 by Analysts at Peel Hunt” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/oxford-biomedica-oxb-given-new-gbx-16-price-target-at-peel-hunt.html.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply